Table 3.
Number and costs of unadjusted 12-month outcomes among patients who received Acthar prescriptions compared to patients who received PMP or IVIG
| 12-month outcome | Unadjusted mean for patients receiving Acthar, mean (median) ± SD (range) | Unadjusted mean for patients receiving PMP or IVIG, mean (median) ± SD (range) | Difference in means for patients receiving Acthar vs. PMP/IVIG (95% CI) | P value |
|---|---|---|---|---|
| Number of all healthcare services | 78 (69) ± 49 (7–385) | 82 (70) ± 49 (9–300) | −4 (−13, 6) | 0.45 |
| Number of Hospitalizations | 0.2 (0) ± 0.6 (0–4) | 0.6 (0) ± 1.5 (0–9) | −0.4 (−0.6, −0.2) | 0.0002 |
| Length of stay (days)a | 3.7 (3) ± 3.6 (0–19) | 7.0 (4) ± 8 (0–45) | −3.3 (−0.2, −6.5) | 0.01 |
| Number of admissions to ICUa | 0.1 (0) ± 0.3 (0–1) | 0.2 (0) ± 0.5 (0–2) | −0.1 (−0.1, 0.3) | 0.18 |
| Number of ER visits | 0.5 (0) ± 1.2 (0–10) | 0.7 (0) ± 1.8 (0–18) | −0.2 (−0.5, 0.1) | 0.24 |
| Number of MS-related ER visitsb | 0.8 (1) ± 1.1 (0–6) | 0.9 (1) ± 1.3 (0–6) | 0.1 (−0.3, 0.6) | 0.52 |
| Number of outpatient services | 31 (23) ± 32 (2–366) | 48 (41) ± 29 (5–170) | −17 (−23, −11) | <0.0001 |
| Number of rehab and long-term care facilities servicesc | 0.1 (0) ± 1.3 (0–19) | 0.3 (0) ± 2.8 (0–40) | −0.2 (−0.6, 0.2) | 0.29 |
| Number of prescriptions | 47 (39) ± 33 (1–179) | 33 (27) ± 34 (0–230) | 14 (8, 20) | <0.0001 |
| Inpatient costs ($) | 3500 (0) ± 14,000 (0–124,000) | 18,800 (0) ± 63,000 (0–490,000) | −15,300 (−24,000, −6500) | 0.001 |
| Outpatient costs ($) | 30,300 (10,200) ± 175,000 (300–2,500,000) | 84,400 (61,000) ± 89,000 (2000–886,000) | −54,100 (−80,000, −28,000) | <0.0001 |
| Long-term care costs ($)d | 19 (0) ± 180 (0–2100) | 329 (0) ± 4000 (0–60,000) | −310 (−850, 230) | 0.26 |
| Medication costs ($) | 87,200 (78,600) ± 55,000 (0–440,000) | 12,300 (4000) ± 18,000 (0–111,000) | 74,900 (67,000, 83,000) | <0.0001 |
| Total costs ($) | 121,000 (94,400) ± 180,000 (3400–2,580,000) | 115,500 (86,000) ± 110,000 (4000–940,000) | 5500 (−22,000, 34,000) | 0.69 |
| 12-month outcome | Frequency (%) among patients receiving Acthar | Frequency (%) among patients receiving PMP or IVIG | Odds ratio (95% CI) | P value |
|---|---|---|---|---|
| Readmission within 30 days (yes/no)a | 7 (29%) | 20 (29%) | 1.0 (0.4–2.7) | 0.98 |
CI confidence interval, ER emergency room, ICU intensive care unit, IVIG intravenous immunoglobulin, MS multiple sclerosis, PMP plasmapheresis
aLength of stay, admissions to ICU, and readmissions within 30 days calculated only among patients with at least one hospitalization (n = 27 among Acthar patients; n = 65 among PMP/IVIG patients)
bMS-related ER visits only calculated among patients with at least 1 ER visit (n = 58 among Acthar patients; n = 63 among PMP/IVIG patients)
cThis includes rehab facilities (inpatient and outpatient), skilled nursing facilities, inpatient long-term care, nursing facilities, custodial care facilities
dLong-term care costs are subsets of outpatient costs